The deal covers a panel of blood-based DNA methylation biomarkers derived in part from Epigenomics' bronchoalveolar lavage-based Epi proLung BL test.
The samples, which include non-small cell lung cancer samples, will be screened for cancer fusions, copy number variations, SNPs, and insertions and deletions.
The Chinese guideline recommends the use of the Septin-9 DNA methylation assay as the standard of care for early colorectal cancer screening.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.